Merck KGaA - Pfizer Alliance
Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US-
IO is top priority for both companies. Benefiting from each other’s strengths & further explore the potential of avelumab, an investigational anti-PD-L1 antibody first discovered & developed by Merck KGaA, the alliance will jointly develop & commercialize avelumab, advance Pfizer’s PD-1 antibody focusing to develop high-priority internat. clin. programs to investigate avelumab as monotherapy & in combination regimens.